Oncomine Chronic Myeloid Leukemia CML Panel Test
Comprehensive Genetic Analysis for Chronic Myeloid Leukemia
The Oncomine Chronic Myeloid Leukemia CML Panel Test represents a cutting-edge advancement in molecular diagnostics for leukemia patients. This comprehensive next-generation sequencing (NGS) panel is specifically designed to detect genetic mutations and fusion genes associated with chronic myeloid leukemia, providing clinicians with critical information for accurate diagnosis, prognosis assessment, and personalized treatment planning.
What Does This Test Measure?
This sophisticated genetic panel analyzes 26 key genes and fusion partners that play crucial roles in CML development and progression:
- Point Mutations: ABL1, ASXL1, CBL, DNMT3A, ETV6, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MYC, MECOM, NRAS, RUNX1, RB1, SF3B1, SH2B3, TP53, TET2, WT1
- Fusion Genes: ABL1, ETV6, JAK2, KMT2A, MECOM, RUNX1
Who Should Consider This Test?
This comprehensive genetic panel is recommended for individuals experiencing:
- Unexplained fatigue, weakness, or persistent tiredness
- Enlarged spleen (splenomegaly) or abdominal discomfort
- Unexplained weight loss or night sweats
- Abnormal blood counts detected during routine examinations
- Patients with newly diagnosed chronic myeloid leukemia
- Individuals showing resistance to tyrosine kinase inhibitor therapy
- Patients requiring treatment monitoring and disease progression assessment
Key Benefits of the Oncomine CML Panel
- Comprehensive Mutation Detection: Identifies multiple genetic abnormalities in a single test
- Personalized Treatment Guidance: Helps select appropriate targeted therapies based on specific mutations
- Prognostic Information: Provides insights into disease progression and treatment response
- Early Detection of Resistance: Identifies mutations associated with treatment resistance
- Minimally Invasive Testing: Requires only blood or bone marrow sample
Understanding Your Test Results
Your results will provide detailed information about detected genetic mutations and their clinical significance:
- Positive for BCR-ABL1 Fusion: Confirms chronic myeloid leukemia diagnosis
- ABL1 Kinase Domain Mutations: Indicates potential resistance to tyrosine kinase inhibitors
- Additional Mutations: May suggest disease progression or transformation
- Negative Results: No detectable mutations in the analyzed genes
Your hematologist or oncologist will interpret these results in the context of your clinical presentation and develop an appropriate treatment plan.
Test Pricing Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Oncomine Chronic Myeloid Leukemia CML Panel Test | $1024 USD | $1138 USD |
Sample Requirements and Processing
Sample Type: 3 mL (2 mL minimum) whole blood OR bone marrow in 1 lavender top (EDTA) tube
Shipping Instructions: Ship refrigerated. DO NOT FREEZE
Required Documentation: Duly filled NGS Test Requisition Form (Form 40) is mandatory
Turnaround Time: Sample by 1st/16th of every month; Report available 15th/30th of same month
Nationwide Availability
We have branches across all major cities in the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our comprehensive network ensures convenient access to this advanced genetic testing service.
Take Control of Your Health Today
Don’t wait to get the comprehensive genetic information you need for optimal CML management. Our experienced team of genetic specialists and hematologists are ready to assist you with this advanced diagnostic testing.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your Oncomine Chronic Myeloid Leukemia CML Panel Test and take the first step toward personalized leukemia care.
